OBJECTIVE: Denosumab is a monoclonal antibody commonly used for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Hypocalcemia is a known adverse effect with denosumab, and we present an unusual case where 2 hypocalcemic events occurred after 1 denosumab treatment. METHODS: A 76-year-old man recently diagnosed with prostate cancer with bone metastasis was given 120 mg denosumab subcutaneously due to extensive bone disease. RESULTS: The patient experienced denosumab-induced hypocalcemia induced by a single denosumab dose which was resolved after 14 days of multiple doses of intravenous calcium gluconate and oral calcium and vitamin D replacement. However, the patient returned with acute kidney injury and severe hypocalcemia (corrected calcium of 6.9 mg/dL) without any additional dose of denosumab. The recovery following the second episode of hypocalcemia was much longer than the initial episode in this patient. CONCLUSION: To our knowledge, this is the first reported case of an additional episode of hypocalcemia following a single denosumab dose. This case highlights the importance of close monitoring of renal function and serum electrolytes following the resolution of denosumab-induced hypocalcemia.
OBJECTIVE: Denosumab is a monoclonal antibody commonly used for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Hypocalcemia is a known adverse effect with denosumab, and we present an unusual case where 2 hypocalcemic events occurred after 1 denosumab treatment. METHODS: A 76-year-old man recently diagnosed with prostate cancer with bone metastasis was given 120 mg denosumab subcutaneously due to extensive bone disease. RESULTS: The patient experienced denosumab-induced hypocalcemia induced by a single denosumab dose which was resolved after 14 days of multiple doses of intravenous calcium gluconate and oral calcium and vitamin D replacement. However, the patient returned with acute kidney injury and severe hypocalcemia (corrected calcium of 6.9 mg/dL) without any additional dose of denosumab. The recovery following the second episode of hypocalcemia was much longer than the initial episode in this patient. CONCLUSION: To our knowledge, this is the first reported case of an additional episode of hypocalcemia following a single denosumab dose. This case highlights the importance of close monitoring of renal function and serum electrolytes following the resolution of denosumab-induced hypocalcemia.
Authors: Prashanth Peddi; Maria A Lopez-Olivo; Gregory F Pratt; Maria E Suarez-Almazor Journal: Cancer Treat Rev Date: 2012-08-13 Impact factor: 12.111
Authors: Karen A Autio; Azeez Farooki; Ilya G Glezerman; Amelia Chan; Coursen W Schneider; Hallie C Barr; Brian M Seyboth; Lewis J Kampel; Daniel C Danila; Dana E Rathkopf; Susan F Slovin; Howard I Scher; Michael J Morris Journal: Clin Genitourin Cancer Date: 2014-11-22 Impact factor: 2.872
Authors: Jean-Jacques Body; Henry G Bone; Richard H de Boer; Alison Stopeck; Catherine Van Poznak; Ronaldo Damião; Karim Fizazi; David H Henry; Toni Ibrahim; Allan Lipton; Fred Saad; Neal Shore; Toshimi Takano; Adam J Shaywitz; Huei Wang; Oswaldo L Bracco; Ada Braun; Paul J Kostenuik Journal: Eur J Cancer Date: 2015-06-17 Impact factor: 9.162